Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, commended Spire Southampton Hospital on the performance of over 100 percutaneous hepatic perfusion (PHP) procedures with CHEMOSAT. PHP with Melphalan/HDS was developed by Delcath Systems as a targeted, whole organ therapy for the liver. The product is commercially available in Europe under the trade name CHEMOSAT, and is being evaluated as an investigational therapy in the U.S. Delcath is currently enrolling patients in the FOCUS trial, a global Phase 3 clinical trial that is investigating PHP with Melphalan/HDS as a treatment for patients with ocular melanoma that has metastasized to the liver.
Shares of Delcath Systems, Inc. (NASDAQ:DCTH) are currently poised at -15.29% from the open today and are trading at $0.03. More than 12,766,214 shares have exchanged hands compared to an average trading volume of 13.74M. At the current pps, the market cap stands at $5.57M. The stock prices of Delcath Systems, Inc. (NASDAQ:DCTH) are currently trading at -99.58% below its 52 week high and -4.00% above its 52 week low.
Delcath Systems, Inc. (NASDAQ:DCTH) is all set to announce its earnings on May 03/b. As per Zack’s analyst ratings, Delcath Systems, Inc. (NASDAQ:DCTH) currently has an average brokerage rating of . On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:DCTH) is $ with a high of $ and a low of $.
Let’s take a look at the technical analysis.
The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oil prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). The 5 day EMA 0.04 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 0.13 is also higher than the current trading price depicting a bearish trend overall.
The relative strength index (RSI) is a momentum oscillator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 24.06 suggesting a bearish price action.
As such, while we believe Delcath Systems, Inc. (NASDAQ:DCTH) represents a compelling growth story exposed to several secularly attractive markets, it would be interesting to see how it fairs for long-term investors.
Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.